Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19577777 | 0.88 | KDM4E (0.33) | HSD17B10KDM4ELMNATDP1 | |
| SCHEMBL2625060 | 0.87 | EPHX1 (0.34) | HSD17B10KDM4E | |
| SCHEMBL29295647 | 0.80 | KDM4E (0.30) | KDM4E | |
| SCHEMBL22795526 | 0.78 | MEN1 (0.34) | — | |
| SCHEMBL9024417 | 0.78 | — | — | |
| SCHEMBL13604089 | 0.78 | HSD17B10 (0.40) | HSD17B10TDP1 | |
| SCHEMBL24607196 | 0.77 | KDM4E (0.36) | HSD17B10KDM4ETDP1 | |
| SCHEMBL21116931 | 0.77 | — | — | |
| Ammonia Solution, Strong SCHEMBL29051935 | 0.76 | KDM4E (0.32) | HSD17B10KDM4ELMNATDP1 | |
| SCHEMBL12186227 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143012-A1 | Macromolecule-Supported TLR Agonists | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2020163630-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCING | Singular Genomics Systems, Inc. (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143012-A1 | Macromolecule-Supported TLR Agonists | TLR8, TLR7, TLR9 | HSD17B10 3811/4885KDM4E 2497/4885LMNA 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.